Background. Many developed nations have made antimicrobial stewardship a priority, creating benchmarks and national standards. Little has been published on the antimicrobial use and stewardship efforts in resource-limited countries due to difficulties collecting data. Viedma Hospital (VH) is a 200-bed hospital in Cochabamba, Bolivia, with no formulized antimicrobial stewardship (AMS) program. To better understand the antibiotic (ABX) use at VH, a point prevalence study was conducted in partnership with UMass Medical School. Point prevalence studies comprehensively review patients prescribed antibiotics using standard criteria in the hospital at a specific point-in-time. Using prevalence studies, areas of opportunity can be identified to focus on limited AMS efforts.
Methods. This was an observational study completed through a 2-day chart review. Patients were included if they were greater than 16 y/o, admitted to the general medicine, surgical or intensive care floors at VH and receiving systemic ABXs at the time of review. Data were collected on location, clinical service, day of hospitalization, sex, age, fever, white blood cell count, immunocompromised status, ABXs prescribed including dose, duration and frequency, the indication for each ABX and microbiology results.
Results. 161 patients were admitted to the hospital during the point prevalence study, of which 85 (52.7%) were prescribed ABXs. Most ABXs were empiric (83%) and frequent indications included intra-abdominal infections (21.3%) and cellulitis (14.5%). Based upon evaluation utilizing standard criteria, 60% of ABXs were considered unnecessary, inappropriate or suboptimal. Common reasons for unnecessary ABXs was the excessive length of antimicrobial therapy (14%), inappropriate dosing of ABXs (8.5%) and no documented infection (51%).
Conclusion. There is limited data discussing ABX utilization in Bolivia, despite continued use and growing resistance. The point prevalence review identified areas of inappropriate use. This evidence will be utilized to focus AMS efforts on the creation of empiric ABX selection, dose and duration recommendations for common indications.
Disclosures. All authors: No reported disclosures. Background. There are fewer board-certified infectious disease (ID) specialists in Japan (n = 1494) than in the United States (n = 8535); therefore, we have insufficient protected time for antimicrobial stewardship activities, and thus, there is a need for an innovative solution.
Methods. This study compared carbapenem consumption between a 24-month baseline period and a 12-month intervention period at the Iizuka Hospital with 1048 inpatient beds in Japan. During the intervention period, a board-certified ID specialist provided daily feedback to prescribers against prolonged carbapenem use (≥14 days) through conversations and medical records. Additionally, we reported through e-mail the weekly point prevalence surveillance data of the long-term carbapenem users for 7-13 and ≥14 days, which were aggregated by each department.
Results. We provided a total of 106 feedbacks regarding carbapenem use for ≥14 days during the intervention period. After the initiation of intervention, the trend of monthly carbapenem consumption changed (coefficient: −0.62; 95% CI: −1.15 to −0.087, P = 0.024), and its overall consumption has decreased (coefficient: −0.098; 95% CI: −0.16 to −0.039, P = 0.002, Figure 1 ) without a change in the in-hospital mortality (P = 0.53) as revealed by segmented regression analysis. Interestingly, the number of monthly carbapenem users, but not the duration of carbapenem use, significantly decreased (coefficient: −3.02; 95% CI: −4.63 to −1.42, P = 0.001, Figure 2 ). An annual estimated saving after the intervention was $82,266 with a cost reduction of 22%.
Conclusion. Our ID specialist-led daily intervention in carbapenem prescription and weekly feedback for long-term carbapenem use were effective in reducing this antibiotic's consumption and consequently the number of carbapenem users. These feedbacks may be useful in changing the behavior of prescribers and promoting appropriate antimicrobial use even in resource-poor settings.
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